Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.

Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.

Abstract: An umbilical cord mesenchymal stem cells (MSCs) and culture method and application thereof, which comprises an MSCs culture step comprising the following substeps: primary culture: culturing Wharton's jelly of an umbilical cord in a serum-free medium under a hypoxic condition; subculture: collecting P1 primary cells to prepare a single cell suspension which is centrifuged to obtain a cell pellet; adding a serum-free medium to the cell pellet, culturing under a hypoxic condition until passage, and continuously culturing up to P2-P3; adding a ligustrazine hydrochloride and a Shenmai injection during each subculture, digesting cells grown to a predetermined fusion degree, and collecting the cells cultured to P6; phenotypic test: testing the phenotype of the collected cells for later use. An MSCs preparation cultured by the method reduces easy aggregation of stem cells, thus avoiding cell adhesion, rouleau formation of red cells and cell cluster embolism after intravenous infusion into human bodies.

Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.

Abstract: The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.

Abstract: A process is provided for bioconversion of carbon monoxide and carbon dioxide. More specifically, the process includes fermenting carbon monoxide and carbon dioxide containing substrate with acetogenic bacteria. The process provides for high levels of carbon monoxide and carbon dioxide conversions and utilization of hydrogen.

Abstract: Technologies for cryopreserving ungulate embryos for implantation into recipient females are described.

Abstract: This application describes liver stem cells (LSC), and differentiated hepatocytes, cholangiocytes, and 3D cellular structures derived therefrom. Methods for producing LSC and mature, differentiated hepatocytes and cholangiocytes in culture are provided. Also provided are cell culture systems and cell culture media for producing a homogenous population of liver stem cells that remain in an undifferentiated state over multiple passages in culture. The LSC and methods are useful for producing homogenous populations of hepatocytes and cholangiocytes for downstream applications. The LSC can be transplanted into subjects to treat liver diseases.

Abstract: The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activities such as antioxidant activity, ?-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity or tight junction protein expression-inducing activity. Accordingly, a certain Lactobacillus sp. strain, certain Bifidobacterium sp. strain or mixture thereof according to the present invention may be used as a functional food or medicinal material useful for the prevention, alleviation or treatment of intestinal damage, liver injury, allergic disease, inflammatory disease, or obesity.

Abstract: The present invention relates to a device and a method for inducing pluripotent cells using energy and, more specifically, has an effect of inducing new type pluripotent cells having pluripotent characteristics by applying energy such as ultrasonic waves, lasers or heat treatment to differentiated cells.

Abstract: Provided are a method of preparing a stem cell-derived epidermal progenitor cell conditioned medium, the method including: differentiating stem cells to stem cell-derived epidermal progenitor cells by culturing the stem cells in a differentiation medium containing ascorbic acid and hydrocortisone; producing a culture of stem cell-derived epidermal progenitor cells by culturing the differentiated stem cell-derived epidermal progenitor cells in a medium; and recovering the stem cell-derived epidermal progenitor cell conditioned medium from the culture of the stem cell-derived epidermal progenitor cells, a stem cell-derived epidermal progenitor cell conditioned medium prepared by the method, and a method of producing a protein from stem cell-derived epidermal progenitor cells, the method including the method of preparing the stem cell-derived epidermal progenitor cell conditioned medium.

Abstract: The invention relates to the fields of biomaterials, tissue engineering and regenerative medicine. More specifically, it relates to biomaterial substrates having precise surface properties and the use thereof to investigate cell-material interactions. Provided is a cell culture system having a biomaterial substrate which has at least a first linear surface gradient oriented orthogonally to a second linear surface gradient, wherein the first gradient and the second gradient are selected from the group consisting of stiffness (S), (aligned) topography (T) and wettability (W). Also provided is a cell screening platform having a combination of at least two, preferably at least three, more preferably four distinct cell culture systems.

Abstract: This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.

Abstract: Particularly effective prebiotic-probiotic combinations including a novel probiotic, B. longum subsp longum, and XOS and B. pseudocatenulatum with Xylo-oligosaccharides are provided, together with methods of identifying synergistic probiotic-prebiotic combinations. Additionally, kits comprising the probiotic(s) and prebiotic(s) are also provided.

Abstract: The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.

Abstract: Provided herein are methods of recovering oil from microorganisms. The methods are useful, for example, in obtaining nutritional oils and/or lipid biofuels. The methods of recovering oil described herein include contacting a population of microorganisms with one or more enzymes under conditions that cause disruption of the microorganisms, concentrating the disrupted microorganisms, and extracting lipids from the disrupted microorganisms at high temperature in the presence of a salt and in the absence of solvent.

Abstract: The present invention relates to a method for mimicking the effects of ionizing radiations on cells, wherein cells are contacted with bleomycin.

Abstract: Provided herein are synthetic living tissue structures comprising multiple layers of fibers deposited in solidified form from a 3D bioprinter, together with kits and methods of use related thereto. The fibers comprise a plurality of mammalian cells dispensed within a solidified biocompatible matrix. The structural integrity of the fiber is maintained upon and after deposition without any additional crosslinking. The fiber is continuously bioprinted through at least two layers of the structure. In one aspect, synthetic muscle tissue structures exhibit a readily assayable contractile functionality.

Abstract: This disclosure pertains to a non-living biological product. Particularly, exosomes derived from stem cells can help restore heart function. According to certain embodiments, a fluid-induced shear stress mechanical stimulation process of stem cells is used to augmented quantity and quality of exosomes produced from stem cells. These exosomes serve as a therapeutic agent for the regenerative repair of diseases, such as diseased heart tissues. Therefore, compositions comprising the exosomes derived from stem cells and methods of treating a degenerative disease by administering the exosomes isolated from stem cells are also provided.

Abstract: Provided herein are cell compositions useful for making artificial liver constructs. The cell composition my include, in combination, (a) hepatocyte cells, (b) Kuppfer cells, (c) hepatic stellate cells, (d) sinusoidal endothelial cells, and (e) cholangiocyte cells.